Bryan, Garnier & Co publishes a new Independent Research Update on AstraZeneca

BUY, FV 3730p vs. 3680p

News published on June Tuesday 11, 2013
Share on

Step by Step

In the space of a couple of weeks AstraZeneca has announced two deals which illustrate fairly well how business development (BD) should strengthen its key therapeutic franchises. First with Omthera Pharmaceuticals and then with Pearl Therapeutics, AstraZeneca has acquired late-stage compounds in cardio-metabolism and respiratory respectively which fuel the pipeline very effectively. Now the piece of the puzzle that is still missing is to make 2013 the trough year.

Full report available to subscribers
Please contact  

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities